Advancing BNCT

Building an ecosystem to advance BNCT as an effective and convenient treatment modality

Founded by Deerfield Management

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways.

Supported by Deerfield Discovery and Development (“3DC”) and Deerfield External Operations

Aviko is supported by a team of drug development and operations professionals from Deerfield Management. The Deerfield 3DC team provides integrated drug development capabilities from early-stage drug discovery through pre-clinical testing and into human clinical trials. The Deerfield external operations team provides a range of financial and business development support to Aviko.


Our team is comprised of leaders in drug development, operations and business development who are committed to advancing boron neutron capture therapy and expanding access to this promising modality to patients in the U.S. We are based at Cure., a healthcare innovation campus in New York City.

Dave Greenwald, Ph.D.

CEO and Board of Directors

Abraham Kometz, M.D.

Board of Directors

Michael Foley, Ph.D.

Board of Directors

Andrew Stamford, Ph.D.

Chief Scientific Officer

Alessandro Mora, Ph.D.

Biopharmaceutical Development

Anthony Barsotti, Ph.D.

Pre-Clinical Pharmacology

Ankita Shah, Ph.D.

Drug Product Development

Christine Brideau

Pre-Clinical Pharmacology

Christopher Freeland, J.D.


Eddie Yang


Ian Hardy, Ph.D.

Chemistry, Manufacturing & Controls

Ivo Lorenz, Ph.D.


JoAnn Scatina, Ph.D.

Pre-Clinical Development (DMPK & Safety)

Joette Pindar, M.S.

Project Management

John Limanto, Ph.D.

Process Chemistry

Jonathan Simansky, MBA


Michael Farrell


Tori Fleek, MBA

Business Development

Zhiqiang Yang, Ph.D.

Medicinal Chemistry

Sam Bakri, M.D., MBA

Business Advisor

Mike Fiore, MBA

Business Advisor